$PFE

Buckley Mortimer J purchased $960K of PFE

Buckley Mortimer J purchased 37,632 shares of PFIZER INC (PFE) at $25.52 ($0.96M total) on 2026-08-05.

Original reporting
SEC EDGAR · Buckley Mortimer J
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

A director open-market purchase is incremental sentiment information, not a new fundamental driver.

02

Market read

Traders may note the insider buy, but there is no accompanying guidance, legal, regulatory, or operational update.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is meaningful versus prior activity.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Pfizer Inc.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer director Buckley Mortimer J bought 37,632 shares in an open-market transaction on 2026-08-05 for about $960K.

Expected impact

Likely limited near-term impact; may modestly support sentiment but is usually not trade-driving alone.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, yet the filing provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity without broader industry news.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Buckley Mortimer J

    Director who purchased 37,632 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PFEHighAI 8/10

International Business: Pfizer net profit up

Pfizer raised its full-year revenue forecast to $62-64bn and earnings to $2.95-$3.05 per share, citing strong demand for drugs like Padcev and Eliquis. CEO Albert Bourla attributed the increase to Q3 performance and confidence in the company's strategy. The company has invested heavily in acquisitions, including Seagen and Metsera, to drive growth. Analysts note that long-term success depends on experimental treatments in development.

$PFEHighAI 9/10

Pfizer Inc. Q3 2026 Earnings Call Summary

Pfizer reported Q3 2026 earnings, highlighting 32% growth in launched and acquired products, including Seagen and Biohaven. The company raised full-year revenue guidance to $62-64B. Management projects high single-digit revenue CAGR from 2028-2033, driven by a strong pipeline. Pfizer also announced a $650M charge related to the Innovent transaction and aims for $2.5B in additional cost savings by 2029.

$PFEHighAI 8/10

Pfizer (PFE) Q3 2026 Earnings Call Transcript

Pfizer (PFE) reported Q3 2026 revenue of $617 billion, up 7% operationally excluding COVID-19 products. Key growth drivers included Padcev, NURTEC, and Lorbrena. The company raised full-year revenue and EPS guidance, citing strong performance and pipeline progress. Pfizer also announced additional cost-saving initiatives. According to the company, strategic acquisitions and R&D investments are driving growth, with plans for multiple Phase 3 trials in 2026 and potential approvals in 2028.

$PFEMed

Pfizer, fresh to China’s obesity market, looks to Viagra model to compete

Pfizer, partnering with Sciwind Biosciences, has launched Ecnoglutide, an obesity drug, in China. Pfizer CEO Albert Bourla compared the strategy to Viagra's success, noting the potential for out-of-pocket consumer purchases. The drug was acquired for $495 million, with Pfizer aiming to leverage its experience in self-pay markets. Pfizer also plans global expansion, focusing on berobenatide and other pipeline assets.